Epigenetic Regulation of miR-17∼92 Contributes to the Pathogenesis of Pulmonary Fibrosis

被引:198
|
作者
Dakhlallah, Duaa [1 ,2 ]
Batte, Kara [1 ]
Wang, Yijie [1 ]
Cantemir-Stone, Carmen Z. [1 ]
Yan, Pearlly [3 ,4 ]
Nuovo, Gerard [4 ,5 ]
Mikhail, Adel [5 ]
Hitchcock, Charles L. [6 ]
Wright, Valerie P. [1 ]
Nana-Sinkam, S. Patrick [1 ]
Piper, Melissa G. [1 ]
Marsh, Clay B. [1 ,2 ]
机构
[1] Davis Heart & Lung Res Inst, Coll Med, Div Pulm Allergy Crit Care & Sleep Med, Columbus, OH USA
[2] Ohio State Univ, Mol Cellular Dev Biol Program, Columbus, OH 43210 USA
[3] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA
[4] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[5] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA
[6] Phylogeny Inc, Powell, OH USA
关键词
microRNA; miR-17 similar to 92; pulmonary fibrosis; DNA methylation; DNMT-1; MIR-17-92; CLUSTER; GENE-EXPRESSION; MYOFIBROBLAST DIFFERENTIATION; DNA; INFLAMMATION; MICRORNAS; PROLIFERATION; FIBROBLASTS; MUTATIONS; PROTEIN;
D O I
10.1164/rccm.201205-0888OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale: Idiopathic pulmonary fibrosis (IPF) is a disease of progressive lung fibrosis with a high mortality rate. In organ repair and remodeling, epigenetic events are important. MicroRNAs (miRNAs) regulate gene expression post-transcriptionally and can target epigenetic molecules important in DNA methylation. The miR-17 similar to 92 miRNA cluster is critical for lung development and lung epithelial cell homeostasis and is predicted to target fibrotic genes and DNA methyltransferase (DNMT)-1 expression. Objectives: We investigated the miR-17 similar to 92 cluster expression and its role in regulating DNA methylation events in IPF lung tissue. Methods: Expression and DNA methylation patterns of miR-17 similar to 92 were determined in human IPF lung tissue and fibroblasts and fibrotic mouse lung tissue. The relationship between the miR-17 similar to 92 cluster and DNMT-1 expression was examined in vitro. Using a murine model of pulmonary fibrosis, we examined the therapeutic potential of the demethylating agent, 5'-aza-2'-deoxycytidine. Measurements and Main Results: Compared with control samples, miR-17 similar to 92 expression was reduced in lung biopsies and lung fibroblasts from patients with IPF, whereas DNMT-1 expression and methylation of the miR-17 similar to 92 promoter was increased. Several miRNAs from the miR-17 similar to 92 cluster targeted DNMT-1 expression resulting in a negative feedback loop. Similarly, miR-17 similar to 92 expression was reduced in the lungs of bleomycin-treated mice. Treatment with 5'-aza-2'-deoxycytidine in a murine bleomycin-induced pulmonary fibrosis model reduced fibrotic gene and DNMT-1 expression, enhanced miR-17 similar to 92 cluster expression, and attenuated pulmonary fibrosis. Conclusions: This study provides insight into the pathobiology of IPF and identifies a novel epigenetic feedback loop between miR-17 similar to 92 and DNMT-1 in lung fibrosis.
引用
收藏
页码:397 / 405
页数:9
相关论文
共 50 条
  • [1] miR-17 ∼92 in lymphocyte development and lymphomagenesis
    Labi, Verena
    Schoeler, Katia
    Melamed, Doron
    CANCER LETTERS, 2019, 446 : 73 - 80
  • [2] MiR-17∼92 ablation impairs liver regeneration in an estrogen-dependent manner
    Zhou, Yongjie
    Zhang, Lei
    Ji, Hongjie
    Lu, Xufeng
    Xia, Jie
    Li, Li
    Chen, Fei
    Bu, Hong
    Shi, Yujun
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2016, 20 (05) : 939 - 948
  • [3] Loss of miR-17∼92 results in dysregulation of Cftr in nephron progenitors
    Phua, Yu Leng
    Chen, Kevin Hong
    Hemker, Shelby L.
    Marrone, April K.
    Bodnar, Andrew J.
    Liu, Xiaoning
    Clugston, Andrew
    Kostka, Dennis
    Butterworth, Michael B.
    Ho, Jacqueline
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2019, 316 (05) : F993 - F1005
  • [4] miR-17∼92 cooperates with RB pathway mutations to promote retinoblastoma
    Conkrite, Karina
    Sundby, Maggie
    Mukai, Shizuo
    Thomson, J. Michael
    Mu, David
    Hammond, Scott M.
    MacPherson, David
    GENES & DEVELOPMENT, 2011, 25 (16) : 1734 - 1745
  • [5] Role of the miR-17∼92 cluster family in cerebellar and medulloblastoma development
    Zindy, Frederique
    Kawauchi, Daisuke
    Lee, Youngsoo
    Ayrault, Olivier
    Ben Merzoug, Leila
    McKinnon, Peter J.
    Ventura, Andrea
    Roussel, Martine F.
    BIOLOGY OPEN, 2014, 3 (07): : 597 - 605
  • [6] Epigenetic Regulation of miR-92a and TET2 and Their Association in Non-Hodgkin Lymphoma
    Elliott, Esther K.
    Hopkins, Lloyd N.
    Hensen, Robert
    Sutherland, Heidi G.
    Haupt, Larisa M.
    Griffiths, Lyn R.
    FRONTIERS IN GENETICS, 2021, 12
  • [7] Attenuation of miR-17∼92 Cluster in Bronchopulmonary Dysplasia
    Rogers, Lynette K.
    Robbins, Mary
    Dakhlallah, Duaa
    Yang, Zhaogang
    Lee, L. James
    Mikhail, Madison
    Nuovo, Gerard
    Pryhuber, Gloria S.
    McGwin, Gerald
    Marsha, Clay B.
    Tipple, Trent E.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2015, 12 (10) : 1506 - 1513
  • [8] PAI-1 is a novel component of the miR-17∼92 signaling that regulates pulmonary artery smooth muscle cell phenotypes
    Chen, Tianji
    Huang, Jason B.
    Dai, Jingbo
    Zhou, Qiyuan
    Raj, J. Usha
    Zhou, Guofei
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2018, 315 (02) : L149 - L161
  • [9] Differential Sensitivity of Target Genes to Translational Repression by miR-17∼92
    Jin, Hyun Yong
    Oda, Hiroyo
    Chen, Pengda
    Yang, Chao
    Zhou, Xiaojuan
    Kang, Seung Goo
    Valentine, Elizabeth
    Kefauver, Jennifer M.
    Liao, Lujian
    Zhang, Yaoyang
    Gonzalez-Martin, Alicia
    Shepherd, Jovan
    Morgan, Gareth J.
    Mondala, Tony S.
    Head, Steven R.
    Kim, Pyeung-Hyeun
    Xiao, Nengming
    Fu, Guo
    Liu, Wen-Hsien
    Han, Jiahuai
    Williamson, James R.
    Xiao, Changchun
    PLOS GENETICS, 2017, 13 (02):
  • [10] A Biogenesis Step Upstream of Microprocessor Controls miR-17∼92 Expression
    Du, Peng
    Wang, Longfei
    Sliz, Piotr
    Gregory, Richard I.
    CELL, 2015, 162 (04) : 885 - 899